VivoSeq
Other

Knee Arthroscopy

2

Pipeline Programs

2

Active Trials

1

Companies Involved

Knee Arthroscopy is an early-stage landscape with 2 programs across 1 company. The most active players are Resolve Therapeutics. 2 programs are in Phase 3.

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

94/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved
No programs

Trial Status

23

clinical trials

Completed17 · 74%
Unknown status3 · 13%
Terminated1 · 4%
Recruiting1 · 4%
Not yet recruiting1 · 4%

Trial Activity

23 trials

Tranexamic Acid for Total Knee Arthroscopy
Completed·TThe Miriam Hospital·Phase 4·NCT04443920·86 enrolled
ACB Versus IA Analgesia in Knee Arthroscopy
Completed··Phase 2·NCT04715152·72 enrolled
Ultrasound-guided Blocks for Ambulatory Knee Arthroscopy
Completed··Phase 4·NCT01837394·60 enrolled
Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy
Completed··N/A·NCT01542723·1,500 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)